<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531790</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-93</org_study_id>
    <nct_id>NCT01531790</nct_id>
  </id_info>
  <brief_title>A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients</brief_title>
  <official_title>A Phase I Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced NSCLC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, tolerability, clinical efficacy and pharmacokinetics of
      continuous Endostar intravenous infusion combined with pemetrexed and carboplatin in advanced
      non small cell lung cancer (NSCLC) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>up to 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 6 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>up to 6 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Endostar plus pemetrexed/carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21 days as one cycle, for a total of 4-6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>d1, AUC 5, i.v.</description>
    <arm_group_label>Endostar plus pemetrexed/carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>d1, 500 mg/m2, i.v.</description>
    <arm_group_label>Endostar plus pemetrexed/carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.</description>
    <arm_group_label>Endostar plus pemetrexed/carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Centrum</intervention_name>
    <description>1 tablet/day</description>
    <arm_group_label>Endostar plus pemetrexed/carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of inoperable stage IIIB/IV non-squamous NSCLC

          -  At least one measurable lesion (RECIST criteria)

          -  Life expectancy &gt; 3 months

          -  ECOG performance status 0-2

          -  Adequate hematologic function: WBC ≥ 3.0×109 /L，ANC ≥ 1.5×109 /L，Hb ≥ 90 g/L，PLT ≥
             100×109 /L

          -  Adequate renal, hepatic and coagulation function

          -  Written informed consent

        Exclusion Criteria:

          -  With uncontrollable malignant pleural effusion or ascites

          -  Thoracic or abdominal surgery within 28 days prior to study entry

          -  History of cerebral stroke or TIA within 6 months prior to study entry

          -  With uncontrollable hypertension, hypertensive emergency or hypertensive
             encephalopathy

          -  Arrhythmia in need of antiarrhythmic treatment, history of angina pectoris, myocardial
             infarction, myocardial ischemia or congestive heart failure (&gt; NYHA class II)

          -  With serious infection (&gt; NCI CTC grade 2)

          -  Gastrointestinal perforation, fistula formation, and/or intra‑abdominal abscess within
             6 months prior to study entry

          -  Symptomatic brain metastases

          -  Patient who has epilepsy

          -  History of HIV infection or chronic hepatitis B or C

          -  Allergic to any of the study drugs

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endostar</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

